Comparison of automated bone scan indexes in patients with prostate cancer: aBSI and BONENAVI.

Takeshi Matsumura¹, Kenichi Nakajima², Atsushi Mizokami³, Hiroshi Wakabayashi¹, Jens Richter⁴, Seigo Kinuya¹

¹Department of Nuclear Medicine, Kanazawa University, 13-1 Takara-Machi, Kanazawa, 920-8640, Japan.

²Department of Nuclear Medicine, Kanazawa University, 13-1 Takara-Machi, Kanazawa, 920-8640, Japan. nakajima@med.kanazawa-u.ac.jp.

³Department of Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.

⁴EXINI Diagnostics, Lund, AB, Sweden.

PubMed DOI

Abstract

OBJECTIVE: Bone scan indexes (BSIs) are frequently applied in Japan, Europe and the USA. The BONENAVI (Japan) and aBSI (Europe and USA) software programs were developed based on different training and validation datasets to calculate BSIs. However, whether they are compatible has not been systematically determined. We compared BSIs generated by these programs in a patient cohort to clarify correla…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.